The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats

Behavioural Brain Research

Volumn 115, Issue 1, 2000, Pages 19-23

  Papp, Mariusz ^a   Vassout, Annick ^b   Gentsch, Conrad ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Depression; NK1 receptor; Rats

Indexed keywords

IMIPRAMINE; NEUROKININ 1 RECEPTOR ANTAGONIST; NKP 608; QUINOLINE 4 CARBOXYLIC ACID 1 (3,5 BISTRIFLUOROMETHYLBENZOYL) 2 (4 CHLOROBENZYL)PIPERIDIN 4 YL AMIDE; SUCROSE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG EFFECT; FEEDING BEHAVIOR; LONG TERM CARE; MALE; MENTAL STRESS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMAL; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHRONIC DISEASE; DEPRESSION; ELECTROSHOCK; IMIPRAMINE; MALE; PIPERIDINES; QUINOLINES; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; STRESS, PSYCHOLOGICAL; SUPPORT, NON-U.S. GOV'T;

EID: 0033833835     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(00)00230-8     Document Type: Article

References (13)

1. Cutler M. Potential anxiolytic activity in gerbils from the substance P (SP) receptor antagonist CGP 49823. J Psychopharmacol 1994;A22.
2. De Lima T.C., Ribeiro S.J. Central effects of tachykinin NK receptor agonists and antagonists on the elevated plus-maze behavior in rats. Soc. Neurosci. Abstr. 22:1996;1154.
3. 1 receptor antagonist in the social interaction test. Pharmacol. Biochem. Behav. 58:1997;747-752.
4. Kramer M., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., MacCoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Carlson E.J., Hargreaves J., Rupniak N.M.J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645.
5. McElroy J.F., Weidemann K.A., Zeller K.L., Jones K.W., Arneric S.P. Acute efficacy of the substance P (NK1) antagonist L-733,060 in rat learned helplessness, a chronic animal model of depression. Soc. Neurosci. Abstr. 25(1):1999;65.
6. Papp M., Moryl E. Antidepressant activity of non-competitive and competitive NMDA antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol. 263:1994;1-7.
7. Papp M., Moryl E., Willner P. Pharmacological validation of the chronic mild stress model of depression. Eur. J. Pharmacol. 296:1996;129-136.
8. Pillard R.C., Fisher S. Normal humans as models for psychopharmacologic therapy. Lipton M.A., Di Mascio A., Kiliam K.F. Psychopharmacology: A Generation of Progress. 1978;783 Raven Press, New York.
9. 1A receptor ligands in the chronic mild stress model of depression. Neuropharmacology. 34:1995;1305-1310.
10. Rupniak N.M.J., Kramer M.S. Discovery of the anti-depressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci. 20:1999;485-490.
11. Teixeira R.M., Santos A.D., Ribeiro S.J., Calixto J.B., Rae G.A., De Lima T.C.M. Effects of administration of tachykinin agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 311:1996;7-14.
12. Vassout A., Schaub M., Gentsch C., Ofner S., Schilling W., Veenstra S. CGP 49823, a novel NK-1 receptor antagonist: behavioural effects. Neuropeptides. 26(Suppl.):1994;S38.
13. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology. 134:1997;319-329.